Asian, European Chip Stocks Slump After Intel Performance Disappoints
By Mauro Orru
Shares of semiconductor companies across Asia and Europe edged lower Friday after Intel's second-quarter sales and third-quarter guidance undershot analysts' forecasts and the group set out plans to lay off thousands of employees this year.
Intel Chief Executive Pat Gelsinger said the chip maker had to adjust to market conditions, particularly a surge in demand for artificial-intelligence chips that is much more acute than he had expected. Intel stock plunged 20% in premarket trading.
Meanwhile in Asia, shares of Taiwan Semiconductor Manufacturing Co., the world's largest contract chip maker, closed down nearly 6% in Taipei. Shares of SoftBank Group, the parent of British chip designer Arm Holdings, closed 8% lower in Tokyo, while chip-making equipment maker Tokyo Electron shed 12%.
In Europe, shares of Dutch semiconductor-equipment maker ASML Holding lost more than 6% in morning trading, while smaller peer ASM International fell 9%. Elsewhere in Europe, shares of Infineon Technologies and Apple supplier STMicroelectronics fell more than 3%.
Write to Mauro Orru at mauro.orru@wsj.com
(END) Dow Jones Newswires
August 02, 2024 04:43 ET (08:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks